Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 12;28(10):2155–2161. doi: 10.1038/s41591-022-01962-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022, corrected publication 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 7 — A, CD45⁺ CD62L⁺ CD27⁺ CD56/16⁻ CD45RO⁺ CCR7⁻ CD45RA⁻ CD4⁻ CD3⁺ CD8⁺ (p = 0.0081); B, CD45⁺ CD33⁺ HLA-DR⁺ CD124⁻ CD14⁺ CD11b⁺ CD66b⁻ CD16⁻ CD33⁺ CD15⁺ (p = 0.0042); C, CD45⁺ HLA-DR⁺ CD124⁻ CD14⁺ CD11b⁺ CD66b⁻ CD16⁻ CD33⁺ CD15⁺ (p = 0.0042); D, CD45⁺ CD94⁺ NKG2D⁺ CD3⁻ CD56⁺ CD117⁻ NKG2A⁺ CD127⁻ CD161⁻ CD16⁺ (p = 0.0036); E, CD45⁺ LIN⁺ HLA-DR⁺ CD33⁺ CD16⁺ CD11b⁺ CD15⁺ (p = 0.0092); F, CD45⁺ HLA-DR⁻ CD69⁺ CD19⁻ CD56⁺ CD16⁻ CD134⁻ CD4⁻ CD3⁺ CD8⁺ (p = 0.0079); G, CD45⁺ CD11b⁺ HLA-DR⁺ CD124⁻ CD14⁺ CD11b⁺ CD66b⁻ CD16⁻ CD33⁺ CD15⁺ (p = 0.0157); H, CD45⁺ γ/δ^- α/β⁺ CD19⁻ CD56⁺ CD16⁻ CD13/14⁻ CD4⁺ CD3⁺ CD8⁻ (p = 0.0113); I, CD45⁺ HLA-DR⁻ CD69⁺ CD3⁺ KIR3DL1⁻ KIR2DL2⁻ NKG2A⁻ CD56⁺ KIR2DL1⁻ CD16⁻ (p < 0.0001); J, CD45⁺ CD107a/b^- CD159c⁺ CD3⁻ KIR3DL1⁻ KIR2DL2⁻ NKp80⁺ CD56⁺ KIR2DL1⁻ CD16⁺ (p = 0.0025); K, CD45⁺ HLA-DR⁻ CD69⁺ CD19⁻ CD56⁺ CD16⁻ CD134⁻ CD4⁻ CD3⁺ CD8⁻ (p = 0.0004); L, CD45⁺ CD16⁺ CD336⁻ CD3⁻ CD244⁺ CD335⁺ NKG2D⁺ CD56⁻ CD161⁺ CD337⁻ (p = 0.0002); M, CD45⁺ γ/δ^- α/β⁺ CD19⁻ CD56⁺ CD16⁻ CD13/14⁻ CD4⁻ CD3⁺ CD8⁻ (p = 0.0191); N, CD45⁺ HLA-DR⁻ CD69⁺ CD3⁺ KIR3DL1⁻ KIR2DL2⁻ NKG2A⁺ CD56⁺ KIR2DL1⁻ CD16⁻ (p = 0.0307); O, CD45⁺ CD62L⁻ CD27⁺ CD56/16⁺ CD45RO⁻ CCR7⁻ CD45RA⁺ CD4⁻ CD3⁺ CD8⁺ (p = 0.0400); P, CD45⁺ CD94⁻ NKG2D⁻ CD3⁺ CD56⁺ CD117⁻ NKG2A⁻ CD127⁺ CD161⁺ CD16⁺ (p = 0.0480); Q, CD45⁺ HLA-DR⁺ CD69⁺ CD3⁻ KIR3DL1⁻ KIR2DL2⁻ NKG2A⁺ CD56⁻ KIR2DL1⁻ CD16⁺ (p = 0.0014); R, CD45⁺ LIN⁻ HLA-DR⁻ CD33⁻ CD16⁺ CD11b⁺ CD15⁺ (p = 0.0030). *Pre-treatment predictor of MPR. LIN included CD19, CD3, and CD56. NKG2A is also known as CD159a, NKG2D as CD314 and KLRK1, KIR2DL1 as CD158a, KIR2DL2 as CD158b, CD335 as NKp46, and CD337 as NKp30. α/β, α/β chains of the T cell receptor; γ/δ, γ/δ chains of the T cell receptor; CCR7, C-C motif chemokine receptor 7; CD, cluster of differentiation; HLA, human leukocyte antigen; KIR, killer cell immunoglobulin-like receptor; KLR, killer cell lectin-like receptor; LIN, lineage; MPR, major pathologic response; NK, natural killer; NKG2, natural killer group protein 2.